What is the pipeline for future medications for obesity?
University of Leicester · Leicester College · +3 more institutions
Abstract
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity…
Citation impact
- FWCI
- 87.89
- Percentile
- 100%
- References
- 126
Authors
4- EMEka MelsonCorresponding
University of Leicester, Leicester College
- UAUzma Ashraf
University of Leicester, Leicester College
- DPDimitris Papamargaritis
University of Leicester, Leicester General Hospital, Kettering General Hospital, Leicester College, NIHR Leicester Biomedical Research Centre
- MJMelanie J. Davies
University of Leicester, Leicester General Hospital, Leicester College
Topics & keywords
- Amylin
- Medicine
- Semaglutide
- Internal medicine
- Endocrinology
- Exenatide
- Incretin
- Agonist
- Good health and well-being